The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis - Schneeweiss, Mathias; Peter, Barbara; Bibi, Siham; Eisenwort, Gregor; Smiljkovic, Dubravka; Blatt, Katharina; Jawhar, Mohamad; Berger, Daniela; Stefanzl, Gabriele; Herndlhofer, Susanne; Greiner, Georg; Hoermann, Gregor; et al. (Haematologica (Roma), 2018)
Keywords: Aged; Aged, 80 and over; Cell Proliferation - drug effects; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology; Male; Mast Cells - drug effects; Mast Cells - metabolism; Mast Cells - pathology; Mastocytosis, Systemic - drug therapy; Mastocytosis, Systemic - metabolism; Mastocytosis, Systemic - pathology; Middle Aged; Mutation; Protein Kinase Inhibitors - pharmacology; Proto-Oncogene Proteins c-kit - antagonists & inhibitors; Receptor, Platelet-Derived Growth Factor alpha - antagonists & inhibitors; Tumor Cells, Cultured